SHEN 211
Alternative Names: SHEN-211Latest Information Update: 25 Mar 2024
At a glance
- Originator JKT Biopharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 06 Mar 2024 JKT Biopharma plans a phase II trial for COVID-2019 infections in China (PO), in April 2024 (NCT06288893)
- 14 Dec 2023 Phase-I clinical trials in Unspecified (In volunteers) in China (PO) (NCT06214858)